Biotechnology A Recombinant Proteins, Monoclonal Antibodies, and Therapeutic Genes, Volume 5a, Second Edition

[bookworm79 0]

Free Download Biotechnology: A: Recombinant Proteins, Monoclonal Antibodies, and Therapeutic Genes, Volume 5a, Second Edition By
1999 | 564 Pages | ISBN: 3527283153 | PDF | 25 MB
In the field of medicinal biotechnology three major developments have caused a revolution in research that has a lot of innovative effects on clinical medicine and future applications on humans. With the availability of tailored recombinant proteins and the opportunity to produce high amounts of monoclonal antibodies new diagnostic applications have emerged and many therapeutic perspectives, e.g. in the treatment of multiple sclerosis and of cancer, are being discussed today. The aim of somatic gene therapy is to re-establish normal cell function by supplying the cells with the respective intact gene. This is a very difficult task and different diseases, e.g. AIDS and several metabolic disorders, are under investigation now. So far first promising approaches exist in cancer therapy. Moreover the book informs about regulatory and economic aspects of these new methods and their applications. Content: Chapter 1 Types and Function of Proteins (pages 1-41): Sabine Wolf and Hans Gunter GassenChapter 2 Sequence and Structure of Proteins (pages 43-86): Frank Eisenhaber and Peer BorkChapter 3 Protein Interactions (pages 87-108): Michael Meyer and Dietmar SchomburgChapter 4 In vitro Folding of Inclusion Body Proteins on an Industrial Scale (pages 110-123): Rainer Rudolph, Hauke Lilie and Elisabeth SchwarzChapter 5 Medical Applications of Recombinant Proteins in Humans and Animals (pages 125-188): Gayle Delmonte WetzelChapter 6 Enzymes for Industrial Applications (pages 189-216): Wolfgang Aehle and Onno MissetChapter 7 Antibody Engineering and Expression (pages 218-244): John R. AdairChapter 8 Manufacture of Therapeutic Antibodies (pages 245-274): Andrew J. Racher, Jerry M. Tong and Julian BonnerjeaChapter 9 Use of Antibodies for Immunopurification (pages 275-288): David J. KingChapter 10 Preclinical Testing of Antibodies: Pharmacology, Kinetics and Immunogenicity (pages 289-302): Roly Foulkes and Sue StephensChapter 11 Preclinical Testing of Antibodies: Safety Aspects (pages 303-310): Ronald W. JamesChapter 12 Therapeutic Applications of Monoclonal Antibodies: A Clinical Overview (pages 311-326): Mark SopwithChapter 13 Antibodies for Sepsis: Some Lessons Learnt (pages 328-341): Steven M. OpalChapter 14 An Engineered Human Antibody for Chronic Therapy: CDP571 (pages 343-353): Mark Sopwith and Sue StephensChapter 15 Antibody Targeted Chemotherapy (pages 355-364): Mark S. Berger, Philip R. Hamann and Mark SopwithChapter 16 ReoPro Clinical Development: A Case Study (pages 365-380): Harlan F. WeismanChapter 17 Overview of Gene Therapy (pages 382-393): Andrew MountainChapter 18 Viral Vectors for Gene Therapy (pages 395-425): Barrie J. CarterChapter 19 Non?Viral Vectors for Gene Therapy (pages 427-441): Neil WeirChapter 20 Issues of Large?Scale Plasmid DNA Manufacturing (pages 443-469): Martin SchleefChapter 21 Gene Therapy for HIV Infection (pages 471-492): Mark C. Poznansky, Myra McClure and Gregor B. AdamsChapter 22 Regulation of Antibodies and Recombinant Proteins (pages 494-516): Julie Foulkes and Gillian TraynorChapter 23 Regulation of Human Gene Therapy (pages 517-530): James ParkerChapter 24 Economic Considerations (pages 531-542): Ian J. Nicholson

Ukryta Zawartość

Treść widoczna tylko dla użytkowników forum DarkSiders. Zaloguj się lub załóż darmowe konto na forum aby uzyskać dostęp bez limitów.

Links are Interchangeable - Single Extraction